Kornimate/medical-research-clean huggingface dataset:
the use of n-acetylcysteine for thrombotic events after allogenic hematopoietic stem cell transplantation

Conditions: Thrombotic Disorder

Summary: we aim to assess the the efficiency and safety of n-acetylcysteine for prevention of thrombotic events after allogenic hematopoietic stem cell transplantation.

the thrombotic events are increasingly recognized complications of hematopoietic cell transplantation (hct) associated with significant morbidity and mortality, which include transplantation-associated thrombotic microangiopathy (ta-tma), sinusoidal obstructive syndrome (sos), deep vein thrombosis (dvt), pulmonary thromboembolism (pte), catheter-related thrombosis (crt), superficial vein thrombosis (svt), etc. there is a complex interplay on balancing the risk for thrombosis and bleeding in these patients, making treatment decisions particularly challenging. emerging studies revealed that endothelial injury is the common underlying mechanism among different thrombotic disorders. there is increasing data that n-acetyl-cysteine (nac) may prevent or improve endothelial dysfunction by inhibiting ros production and preventing endothelial apoptosis. our previous study showed low dose nac could decrease the incidence of ta-tma. in this study, we aim to assess the the efficiency and safety of n-acetylcysteine for prevention of thrombotic events after allogenic hematopoietic stem cell transplantation.

Eligibility criteria:
inclusion criteria: 1. aged 16-70 years old 2. diagnosed as myeloid malignancies, and about to undergo allo-hsct; 3. ecog: 0-2; 4. expected survival longer than 1 month exclusion criteria: 1. allergic to any components of nac; 2. severe dysfunction of heart, liver, lung and kidney; 3. relapse before hsct; 4. a history of bronchial asthma, bronchospasm or moderate / severe gastrohelcosis.

Keywords: thrombotic disorder hematopoietic stem cell transplantation
efficacy of nasogastric tube application in postoperative care of esophagectomy

Conditions: Esophageal Cancer

Summary: nasogastric decompression is standard practice after esophageal resection in most centers because it is expected to reduce the incidence of esophagogastric anastomotic leakage by preventing overdistension of the gastric conduit. most esophageal surgeons have been reluctant to move away from this tradition because of the considerable morbidity of anastomotic leaks after esophagectomy. however, a contrarian view is that the use of prolonged ngd may increase the incidence of postoperative pulmonary complications by promoting aspiration. considering the numerous complications caused by using the tube and the uncertainty about its usefulness and the scarcity of studies conducted on the subject, particularly in patients with esophageal cancer, the necessity of using the tube in these types of cases is investigated in the present study.

methods in this clinical trial, patients with esophageal cancer were randomized into groups with ng tube and without ng tube after surgery. sequence generation was performed using a computer-generated sequence of random numbers with permuted blocks. standard postoperative management protocols were followed in both groups to avoid potential bias, which including preoperation nasogastric decompression. thoracic esophageal mobilization and mediastinal lymphadenectomy were performed by open thoracotomy surgery. the abdominal part of the surgery was performed by laparotomy, gastric tube reconstruction was performed using linear staplers, and the conduit was brought up to the neck through the posterior mediastinal route. a cervical esophagogastric anastomosis was performed by stapled (linear) techniques. all patients were mobilized early, began early enteral feeding through jejunostomy tubes. randomization was performed during the surgery. the group without ng tube after surgery will discharge the ng tube during the surgery. while the control group(group with ng tube after surgery) will discharge the ng tube 6-7days after surgery. the variables recorded for each patient included pulmonary complications, wound complications, anastomosis leak as well as the duration of postoperative hospitalization and the need for placing replacing the ng tube.

Eligibility criteria:
inclusion criteria: patients who were fit for esophageal resection and underwent transthoracic or transhiatal esophagectomy with gastric tube reconstruction. - exclusion criteria: 1. stage investigations indicating unresectable advanced disease(t4 or m1a,m1b). 2. patients with any other serious underlying medical condition that would impair the ability of the patient to receive or comply with protocol treatment. 3. patients with unstable situation after surgery (eg, need ventilation and icu treatment) 4. patients medically unfit for surgical resection. 5. patients with pulmonary reserve inadequate to undergo thoracotomy and extensive mediastinal lymphadenectomy. 6. mentally disabled. 7. expected life duration of less than 3 months. 8. patients undergoing colonic reconstruction.

Keywords: esophageal cancer nasogastric tube
predictive factors of visual recovery after paraoptic tumors removal

Conditions: Tuberculum Sellae Meningioma

Summary: paraoptic tumors - including mostly sellar meningiomas, pituitary gland adenomas and craniopharyngiomas - classically affect the visual function. some preoperative factors, determined on retrospective studies, are known to constitute bad prognostic factors, such as duration of symptoms and retinal nerve fiber layer thinning on oct. we propose to perform a single center prospective study in which detailed preoperative ophthalmological and radiological criteria will be collected before surgery. intraoperative information will be noted as well. all these data will be statistically examined regarding the postoperative visual recovery at 3, 6 and 12 months


Eligibility criteria:
inclusion criteria: * tuberculum sellae meningioma surgical indication exclusion criteria: * surgical contra indication mri contra indication optical disease
study to evaluate adverse events and change in disease activity in participants between 6 and 17 years with moderate to severe plaque psoriasis treated with subcutaneous (sc) injection of risankizumab who have completed participation in study m19-977

Conditions: Psoriasis

Summary: psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. this study evaluates adverse events and change in disease activity with risankizumab in pediatric participants with moderate to severe plaque psoriasis who completed the study m19-977. risankizumab is an approved drug for treatment of moderate to severe plaque psoriasis in adults and is being studied in the pediatric population (6 to 17 years). a maximum of 132 participants will be enrolled in the study across approximately 50 sites worldwide. participants will receive subcutaneous injection of risankizumab every 12 weeks for 204 weeks and are followed up for safety for 20 weeks after last dose. there may be higher treatment burden for participants in this trial compared to their standard of care. participants will attend regular visits during the study at a hospital or clinic. the effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.


Eligibility criteria:
inclusion criteria: --participants who have completed participation in study m19-977 and who meet all eligibility criteria for participation in study m19-973 will be allowed to enroll in study m19-973. exclusion criteria: --participants who have developed any discontinuation criteria as defined in study m19-977.

Keywords: plaque psoriasis risankizumab skyrizi abbv-066 bi 655066 risankizumab-rzaa
prospective pilot study on metabolism and weight changes in topiramate-treated epilepsy patients

Conditions: Epilepsy; Epilepsies, Partial; Epilepsy, Generalized; Seizures

Summary: the purpose of this study is to assess a possible predictor for weight loss seen in epilepsy patients treated with topiramate.

topiramate has been shown to be an effective anti-epileptic medication with a good safety profile. in clinical trials, some patients have experienced substantial weight loss. this prospective single center, open, pilot study will investigate whether there is any metabolic predictor for the weight loss. the patients will receive daily oral dose of topiramate in addition to anti-epileptic medications already prescribed by their physicians. a battery of metabolic tests including body mass index (bmi), lean body mass, blood lipids and fasting glucose in tandem with other examinations will be taken before dispensing of topiramate, after 3 months and at the final visit. the study hypothesis is metabolic test results will provide a predictor of weight loss with topiramate. patients will receive between 25 to 400mg daily of topiramate by mouth in addition to current anti-epileptic medications for up to 1 year. dose will be adjusted (up to 1000 mg daily) by the investigators depending on the patients' clinical response.

Eligibility criteria:
inclusion criteria: * a diagnosis of partial onset epilepsy, with or without secondary generalization. patients with a diagnosis of epilepsy characterized by primary generalized tonic-clonic seizures may also qualify * currently taking one or more anti-epileptic medications on a stable dose for one month * weight between 40 and 130 kg (88 to 286 lbs) * female patients must be postmenopausal for at least 1 year, surgically incapable of childbearing, practicing an acceptable method of contraception (requires negative pregnancy test). exclusion criteria: * patients with rapidly progressive disorders that may impair their weight or their reliable participation in the study * patients prone to severe malabsorption and/or metabolic disorders * patients who have mental retardation or impairment which would confound the interpretation of this study * history (within the past six months) of a psychiatric or mood disorder requiring medical treatment * history of poor compliance with past anti-epileptic drug therapy * suicide attempt in the past five years

Keywords: epilepsy partial epilepsy secondary generalized epilepsy primary generalized epilepsy tonic-clonic seizures topiramate weight loss
oxytocin's effects on face attentional processing

Conditions: Healthy

Summary: to investigate whether intranasal oxytocin (24iu) treatment has a regulatory effect on attentional processing of emotional faces.

in a placebo-controlled double-blind between-subject design experiment, investigators plan to investigate the effect of oxytocin treatment on attentional processing of emotional faces. subjects complete questionnaires in chinese versions before treatment administration, including the beck depression inventory, autism spectrum quotient , trait anxiety inventory, toronto alexithymia scale, multidimentional assessment of interoceptive awareness. this experiment consists of two tasks including emotional face cue-target task and visual search task. in the first task, subjects need to make a response to judge the position of target after a cue-target is presented. in the second task, subjects are asked to search the target "u" or inverted "u" placed on the nose of emotional/neutral faces and make an choices based on their oorientation. during these phases, subjects' response accuracy, response time and electrophysiological activity (erp) are recorded.

Eligibility criteria:
inclusion criteria: * healthy subjects without past or current psychiatric or neurological disorders. exclusion criteria: * history of head injury * medical or psychiatric illness

Keywords: oxytocin emotional faces attention n2pc
morphine versus ketorolac in low back pain

Conditions: Low Back Pain

Summary: the study is prospective, double blinded, randomised controlled and has the purpose to compare the analgesic effects of ketorolac or morphine intravenous in low back pain.

the study will take place in the emergency department of the clinical emergency hospital bucharest and will compare the analgesic effects of ketorolac tromethamine against morphine in low back pain. the patients will be randomised to receive either ketorolac 30 mg intravenous (diluted in 20 ml of 0,9% saline) or morphine 0,1 mg/kg weight intravenous. a scale of 1-10 will be used for measuring the pain, and the effects of the treatment will be evaluated at 15 minutes and 30 minutes from the administration of the drugs. after 30 minutes if there is no significant reduction of the pain a rescue therapy will be used : acetaminophen 1 g, sodic metamizole 1g both diluted in 500 ml saline and the other medication not used from the study (morphine or ketorolac tromethamine).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of musculoskeletal low back pain * grade 5 pain on a 1-10 visual pain scale exclusion criteria: * contraindications of ketorolac or opioids * pregnancy * known allergies to ketorolac or opioids * post-traumatic low back pain * refusal of participation

Keywords: ketorolac pain relieve morphine
the peer-delivered "mind. body. voice." program for high school women

Conditions: Eating Disorders in Adolescence

Summary: this study will evaluate the impact of a program (called mind. body. voice. or "mbv") that was collaboratively designed by youth, educators, and researchers, informed by the body project (becker et al., 2013; stice et al., 2019), youth participatory action research, and an extended co-design process. the study evaluates the impact of the mbv program on key aspects of mental health and well-being; specifically, body image and disordered eating symptoms, identity and agency, social and self-constructs, physical health and mood at five time points over the course of a year. students will be recruited from two high schools and will be randomized to receive the mbv program or an assessment-only control group.

eating disorders have the highest mortality rate of any psychiatric condition and are the second leading cause of mental health disability among young women. given that eating disorders have their peak onset during adolescence (ages 16-19), prevention efforts among adolescent women are critical in order to avert the onset of these chronic and disabling disorders. the mbv program targets body image and appearance related pressures, awareness of body sensations, and agency and community building skills.the program consists of 10 weekly sessions and is delivered by peer facilitators. this study will implement and evaluate the mbv program at the high school level in order to examine the extent to which the program influences young women's mental health and well-being, particularly related to eating disorder risk factors and symptoms. utilizing a longitudinal randomized controlled trial, the study seeks to address the following aims: 1. to examine the impact of the mbv program on key aspects of mental health and well-being; specifically, body image and disordered eating symptoms, identity and agency, social and self- constructs, physical health and mood among participating high school women. 2. to explore young women's experiences of participating in the program, including strengths and limitations and perspectives on specific activities.

Eligibility criteria:
inclusion criteria: * high school women, grades 9-12 exclusion criteria: * prior participation in the body project

Keywords: eating disorder prevention female adolescence peer delivery
pretreatment with estradiol valerate

Conditions: Infertility

Summary: the present study is set up to evaluate the efficacy of a programmation by administration of estrogen valerate during 6 or more consecutive days. in this prospective randomised trial, we study the impact of administration of progynova® during 6, 7,8 9 or 10 consecutive days during the luteo-follicular transition period of the menstrual cycle.

see section interventions

Eligibility criteria:
inclusion criteria: \< 36 years old on day of randomisation fsh \< 12 (in the early follicular phase) normal ultrasound scan, i.e. presence of both ovaries, without evidence of abnormality within 6 months prior to randomisation. regular menstrual cycles of 21-35 days, presumed to be ovulatory. bmi between 18 and 29 (both inclusive) 1st or 2nd trial ivf or icsi exclusion criteria: ≥ 36 years old on day of randomisation endometriosis ≥ grade 3 pcos poor responders (development of \< 4 follicles in a previous ivf/icsi cycle) endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney)

Keywords: icsi gnrh antagonists planning
the effect of peer-mentor support for older vulnerable patients with ischemic heart disease

Conditions: Ischemic Heart Disease

Summary: background: advanced treatment regimens have reduced cardiovascular mortality resulting in an increasingly older ischemic heart disease (ihd) population in need of cardiac rehabilitation (cr) , the majority (74%) is above 60 years. the positive effect of cr is well established; cr reduces cardiovascular mortality, lowers hospital admissions, and improves quality of life among patients with ihd. these positive effects of cr has also been established among older patients. the inherent problem lies in the low attendance rate, often below 50%. several studies, including studies from denmark, have shown that low participation in cr is most prevalent among older, vulnerable and female patients. the notion vulnerable covers patients with low socioeconomic position (sep), patients with non-western background and patients living alone, as these groups have particularly low cr attendance. effective interventions aiming at increasing cr attendance among these low attending groups are thus warranted and the current study will seek to address this. aim: to test the effect of a peer-mentor intervention among older vulnerable ihd patients. design and methods: the study is designed as a two arm rct-study applying mixed methods. power calculations were based upon primary outcome 'cardiac rehabilitation (cr) attendance'. proportion attending cr in control group was set at 25% and intervention group at 50% based upon previous research. with a 5% significance level and 80% power. 110 patients were required (55 in each group) to have a 80% chance of detecting, as significant at the 5% level, an increase in the primary outcome measure from 25% in the control group to 50% in the experimental group. expected dropout was 6%. i.e., in total 117 patients are enrolled. patients (n=117) are recruited by a dedicated research nurse before discharge from the cardiology department at nordsjællands hospital and randomized (with 1:1 individual randomisation) to peer-mentor intervention or usual care. data is collected through both qualitative and quantitative data (mixed methods). data is collected at three timepoints, baseline, 12 weeks and 24 weeks. the patients (mentees) are matched with peer-mentors. peer-mentoring (i.e. mentoring by a person with a similar life situation or health problem as one self) is a low-cost intervention that holds the potential to improve cr attendance and improve physical and psychological outcomes among older patients. peer-mentors are role models who can guide and support patients overcoming barriers of cr attendance. peer-mentoring is unexplored in a cr setting among older, female and vulnerable ihd patients; establishing the novelty of the current study.


Eligibility criteria:
inclusion criteria: * ≥65 years and diagnosed with ihd and referred to cr and female or low sep or single living or non-western background exclusion criteria: * patients unable to provide written consent
a closed-loop brain-computer interface for stroke

Conditions: Stroke

Summary: it may be hard to acquire stable sensorimotor rhythm from the affected motor cortex for patient without a response of paretic hand. a few studies suggest two ways to approaching closed-loop therapy: peripherally extracting the residual signals, for example electromyogram (emg) at proximal muscles (deltoids) and centrally extracting the activity patterns from unaffected hemisphere during attempting to move paretic hand. therefore, understanding neural signatures of residual upper extremity movement among stroke patients might help in discovering potential therapeutic target and developing tailored brain-computer interface (bci) therapy. additionally, 59.4% of stroke patients in acute stage impair at least one somatosensory modality. it remains unclear whether the patient with somatosensory impairment hinder bci effect.

investigators will consecutively enroll subacute (1-4 weeks after stroke onset) patients with first-time, unilateral, subcortical stroke and age-matched healthy controls. all participants will carry on 2 sequential experiments. in the first experiment, participants will perform 2 motor tasks using either paretic/nondominant upper extremity or non-paretic/dominant upper extremity, called motor attempt (m) condition or calibration condition. the second experiment contains 3 conditions: cyclic functional electrical stimulation (cfes), cfes during motor attempt (m-cfes), and functional electrical stimulation during brain-computer interface (bci-fes) in random order. the sensorimotor oscillations from the electroencephalography (eeg), upper extremity sensorimotor function score (fugl-meyer test, action research arm test, and revised nottingham sensation assessment), corticospinal excitability from the transcranial magnetic stimulation (tms), and resting-state functional and structural neuroimage from magnetic resonance imaging (mri) will be assessed before and after the final experiment, as well as 3 months after stroke.

Eligibility criteria:
inclusion criteria: * first-ever, unilateral infarction or hemorrhage at middle cerebral artery or posterior cerebral artery territory * early subacute phase of stroke (between 1 and 4 weeks after stroke onset) exclusion criteria: * electroencephagraphy feature is not usable * fugl-meyer assessment of upper extremity score is over 50 * ataxia * global aphasia * concomitant neurological diseases * psychiatric diseases * participating in other interventional research during this period * other conditions might interfere with experiment

Keywords: stroke sensorimotor rhyme brain-computer interface